Barr's Portia approved and launched in Canada
Barr Pharmaceuticals says that its subsidiary, Barr Laboratories, has received approval from the Therapeutic Products Directorate of Health Canada for its Abbreviated New Drug Submission for its Portia generic oral contraceptive as a generic equivalent of Wyeth Laboratories' Min-Ovral (levonorgestrel and ethinyl estradiol) tablets. This represents the first approval of a generic oral contraceptive for Canadian consumers.
Under the terms of an agreement with Apotex, Barr will manufacture the product and the former will market it in Canada. Apotex will record the Canadian sales of Portia and will pay Barr a royalty from these.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze